Ecraid
@ecraid.bsky.social
The European Clinical Research Alliance for Infectious Diseases is a not-for profit foundation that advances clinical research in infectious diseases.
🚨 The countdown is on for the Ecraid Foundation Science Meeting 2026! Join us for high-impact scientific exchange and collaborative networking.
🥼 Access to infectious disease experts
🏆 Accreditation by ABIC and NVMM
Don’t miss your chance to register: www.eventbrite.nl/e/ecraid-fou...
🥼 Access to infectious disease experts
🏆 Accreditation by ABIC and NVMM
Don’t miss your chance to register: www.eventbrite.nl/e/ecraid-fou...
Ecraid Foundation Science Meeting
Engage with Europe’s first dedicated clinical research network for infectious diseases, meet ID experts and foster collaboration.
www.eventbrite.nl
December 31, 2025 at 8:41 AM
🚨 The countdown is on for the Ecraid Foundation Science Meeting 2026! Join us for high-impact scientific exchange and collaborative networking.
🥼 Access to infectious disease experts
🏆 Accreditation by ABIC and NVMM
Don’t miss your chance to register: www.eventbrite.nl/e/ecraid-fou...
🥼 Access to infectious disease experts
🏆 Accreditation by ABIC and NVMM
Don’t miss your chance to register: www.eventbrite.nl/e/ecraid-fou...
🎧Recording available!
Tune into this webinar in collaboration with @europeanrespsoc.bsky.social on #PandemicPreparedness 👇
channel.ersnet.org/media-114951...
Tune into this webinar in collaboration with @europeanrespsoc.bsky.social on #PandemicPreparedness 👇
channel.ersnet.org/media-114951...
December 29, 2025 at 11:19 AM
🎧Recording available!
Tune into this webinar in collaboration with @europeanrespsoc.bsky.social on #PandemicPreparedness 👇
channel.ersnet.org/media-114951...
Tune into this webinar in collaboration with @europeanrespsoc.bsky.social on #PandemicPreparedness 👇
channel.ersnet.org/media-114951...
As we close out 2025, we look back on a truly landmark year for Ecraid: one defined by growth, collaboration, and impact. Thank you to our partners, collaborators, sites, investigators, and team members for your commitment and trust.
Happy holidays, and all the best for the year ahead 🌟
Happy holidays, and all the best for the year ahead 🌟
December 24, 2025 at 9:02 AM
As we close out 2025, we look back on a truly landmark year for Ecraid: one defined by growth, collaboration, and impact. Thank you to our partners, collaborators, sites, investigators, and team members for your commitment and trust.
Happy holidays, and all the best for the year ahead 🌟
Happy holidays, and all the best for the year ahead 🌟
🎉 Amazing milestones reached in three of our perpetual observational studies (POS)! We are tremendously proud of ALL the site teams behind these studies, for making it happen as 2025 comes to an end - a great way to wrap up the year!
Thank you!
ecraid.eu/ecraid-base/...
Thank you!
ecraid.eu/ecraid-base/...
December 23, 2025 at 9:30 AM
🎉 Amazing milestones reached in three of our perpetual observational studies (POS)! We are tremendously proud of ALL the site teams behind these studies, for making it happen as 2025 comes to an end - a great way to wrap up the year!
Thank you!
ecraid.eu/ecraid-base/...
Thank you!
ecraid.eu/ecraid-base/...
Announcing Module 2 of the Ecraid x @ESCMID online course on Biomedical Data & Sample Governance: 'How to design your data governance framework' in collaboration with CoMeCT, IDDO, CERCLE, @who.int and @tghn-news.bsky.social
🎧👉 www.escmid.org/education/ed...
#DataGovernance #EpidemicPreparedness
🎧👉 www.escmid.org/education/ed...
#DataGovernance #EpidemicPreparedness
December 22, 2025 at 12:28 PM
Announcing Module 2 of the Ecraid x @ESCMID online course on Biomedical Data & Sample Governance: 'How to design your data governance framework' in collaboration with CoMeCT, IDDO, CERCLE, @who.int and @tghn-news.bsky.social
🎧👉 www.escmid.org/education/ed...
#DataGovernance #EpidemicPreparedness
🎧👉 www.escmid.org/education/ed...
#DataGovernance #EpidemicPreparedness
📩Our final newsletter of 2025 is out!
As we close 2025, we also say farewell to our CEO, @marcbonten.bsky.social. We are proud of what we have achieved together over the years & look ahead with confidence to 2026, welcoming @lenniederde.bsky.social onboard!
Read more & subscribe: bit.ly/Dec25Ecraid
As we close 2025, we also say farewell to our CEO, @marcbonten.bsky.social. We are proud of what we have achieved together over the years & look ahead with confidence to 2026, welcoming @lenniederde.bsky.social onboard!
Read more & subscribe: bit.ly/Dec25Ecraid
December 18, 2025 at 1:18 PM
📩Our final newsletter of 2025 is out!
As we close 2025, we also say farewell to our CEO, @marcbonten.bsky.social. We are proud of what we have achieved together over the years & look ahead with confidence to 2026, welcoming @lenniederde.bsky.social onboard!
Read more & subscribe: bit.ly/Dec25Ecraid
As we close 2025, we also say farewell to our CEO, @marcbonten.bsky.social. We are proud of what we have achieved together over the years & look ahead with confidence to 2026, welcoming @lenniederde.bsky.social onboard!
Read more & subscribe: bit.ly/Dec25Ecraid
The rationale & design of the #PNEUMO study Europe was recently published!
👉 bit.ly/3MBR6d4
Now in its final year, the studies primary goal is to estimate the incidence of pneumococcal #pneumonia & serotype prevalence among adults in Europe.
#ClinicalTrials #InfectiousDiseases #ResearchSky #IDSky
👉 bit.ly/3MBR6d4
Now in its final year, the studies primary goal is to estimate the incidence of pneumococcal #pneumonia & serotype prevalence among adults in Europe.
#ClinicalTrials #InfectiousDiseases #ResearchSky #IDSky
December 16, 2025 at 8:16 AM
The rationale & design of the #PNEUMO study Europe was recently published!
👉 bit.ly/3MBR6d4
Now in its final year, the studies primary goal is to estimate the incidence of pneumococcal #pneumonia & serotype prevalence among adults in Europe.
#ClinicalTrials #InfectiousDiseases #ResearchSky #IDSky
👉 bit.ly/3MBR6d4
Now in its final year, the studies primary goal is to estimate the incidence of pneumococcal #pneumonia & serotype prevalence among adults in Europe.
#ClinicalTrials #InfectiousDiseases #ResearchSky #IDSky
Join the Ecraid Foundation Science Meeting on 2 February 2026 in Utrecht! This two-day academic event brings together leading experts, researchers & infectious disease opinion leaders from across Europe to advance clinical research in ID.
More info & tickets: www.eventbrite.nl/e/ecraid-fou...
More info & tickets: www.eventbrite.nl/e/ecraid-fou...
Ecraid Foundation Science Meeting
Engage with Europe’s first dedicated clinical research network for infectious diseases, meet ID experts and foster collaboration.
www.eventbrite.nl
December 15, 2025 at 1:20 PM
Join the Ecraid Foundation Science Meeting on 2 February 2026 in Utrecht! This two-day academic event brings together leading experts, researchers & infectious disease opinion leaders from across Europe to advance clinical research in ID.
More info & tickets: www.eventbrite.nl/e/ecraid-fou...
More info & tickets: www.eventbrite.nl/e/ecraid-fou...
Trainings, talent & top science: the last Ecraid Learning Newsletter of the year is out!
Filled to the brim with exciting courses, testimonials from participants at past ones, freshly-published science and interesting interviews & blogs!
👉🏽https://bit.ly/LearningDecEcraid
Filled to the brim with exciting courses, testimonials from participants at past ones, freshly-published science and interesting interviews & blogs!
👉🏽https://bit.ly/LearningDecEcraid
December 15, 2025 at 9:48 AM
Trainings, talent & top science: the last Ecraid Learning Newsletter of the year is out!
Filled to the brim with exciting courses, testimonials from participants at past ones, freshly-published science and interesting interviews & blogs!
👉🏽https://bit.ly/LearningDecEcraid
Filled to the brim with exciting courses, testimonials from participants at past ones, freshly-published science and interesting interviews & blogs!
👉🏽https://bit.ly/LearningDecEcraid
Ecraid joins the #PrIMAVeRa_AMR Consortium to accelerate #AMR modelling!
This strategic partnership is a powerful step forward in the fight against #AntimicrobialResistance.
👉🏽Learn more about this vital collaboration & its impact on public health: www.ecraid.eu/news/ecraid-...
#StopSuperbugs
This strategic partnership is a powerful step forward in the fight against #AntimicrobialResistance.
👉🏽Learn more about this vital collaboration & its impact on public health: www.ecraid.eu/news/ecraid-...
#StopSuperbugs
December 10, 2025 at 1:33 PM
Ecraid joins the #PrIMAVeRa_AMR Consortium to accelerate #AMR modelling!
This strategic partnership is a powerful step forward in the fight against #AntimicrobialResistance.
👉🏽Learn more about this vital collaboration & its impact on public health: www.ecraid.eu/news/ecraid-...
#StopSuperbugs
This strategic partnership is a powerful step forward in the fight against #AntimicrobialResistance.
👉🏽Learn more about this vital collaboration & its impact on public health: www.ecraid.eu/news/ecraid-...
#StopSuperbugs
Ventilator-associated pneumonia can be a challenge to study in traditional randomised controlled trials due to low patient and event numbers. This recent paper explores whether adaptive trial designs can make VAP prevention trials more efficient
link.springer.com/article/10.1...
link.springer.com/article/10.1...
December 4, 2025 at 1:03 PM
Ventilator-associated pneumonia can be a challenge to study in traditional randomised controlled trials due to low patient and event numbers. This recent paper explores whether adaptive trial designs can make VAP prevention trials more efficient
link.springer.com/article/10.1...
link.springer.com/article/10.1...
Proud to be a part of the PrIMAVeRA consortium and contribute to developing comprehensive mathematical models to predict the impact of #vaccines and mAbs on reducing the burden of #anitmicrobialresistance 👇 🎉
🤝 The #PrIMAVeRa_AMR consortium welcomes its newest partner: the European Clinical Research Alliance on Infectious Diseases (@ecraid.bsky.social)!
🔗 Read more: www.primavera-amr.eu/post/ecraid-...
#EUfunded @ihieurope.bsky.social @ecraid.bsky.social
🔗 Read more: www.primavera-amr.eu/post/ecraid-...
#EUfunded @ihieurope.bsky.social @ecraid.bsky.social
Ecraid becomes the newest member of the PrIMAVeRa Consortium
PrIMAVeRa welcomes Ecraid, the newest member of the project consortium.
www.primavera-amr.eu
November 20, 2025 at 1:51 PM
Proud to be a part of the PrIMAVeRA consortium and contribute to developing comprehensive mathematical models to predict the impact of #vaccines and mAbs on reducing the burden of #anitmicrobialresistance 👇 🎉
📩 Our latest newsletter is out! We’re thrilled to welcome our new CEO, @lenniederde.bsky.social, marking a fresh chapter in Ecraid’s journey. Other updates in this edition:
✅ ECRAID-Base: new publications
✅ ECRAID-Prime: launch of third treatment arm
And more…
📫 Subscribe now: bit.ly/NovEcraid
✅ ECRAID-Base: new publications
✅ ECRAID-Prime: launch of third treatment arm
And more…
📫 Subscribe now: bit.ly/NovEcraid
November 13, 2025 at 1:31 PM
📩 Our latest newsletter is out! We’re thrilled to welcome our new CEO, @lenniederde.bsky.social, marking a fresh chapter in Ecraid’s journey. Other updates in this edition:
✅ ECRAID-Base: new publications
✅ ECRAID-Prime: launch of third treatment arm
And more…
📫 Subscribe now: bit.ly/NovEcraid
✅ ECRAID-Base: new publications
✅ ECRAID-Prime: launch of third treatment arm
And more…
📫 Subscribe now: bit.ly/NovEcraid
We are very pleased to announce Lennie Derde as Ecraid's new Chief Executive Officer effective 1 January 2026. She will succeed Ecraid’s co-founder @marcbonten.bsky.social
Read more 👉 ecraid.eu/articles/len...
@umcutrecht.bsky.social @ec.europa.eu @horizoneu.bsky.social
Read more 👉 ecraid.eu/articles/len...
@umcutrecht.bsky.social @ec.europa.eu @horizoneu.bsky.social
November 12, 2025 at 1:43 PM
We are very pleased to announce Lennie Derde as Ecraid's new Chief Executive Officer effective 1 January 2026. She will succeed Ecraid’s co-founder @marcbonten.bsky.social
Read more 👉 ecraid.eu/articles/len...
@umcutrecht.bsky.social @ec.europa.eu @horizoneu.bsky.social
Read more 👉 ecraid.eu/articles/len...
@umcutrecht.bsky.social @ec.europa.eu @horizoneu.bsky.social
💉Early BCG vaccination could save newborn lives. A new RCT from India shows a nearly 20% drop in neonatal mortality simply by administering vaccines earlier.
🔗 Read the latest blog post by @marcbonten.bsky.social: letstalkscience.eu/2025/11/04/l...
Join the discussion 👇🏽
🔗 Read the latest blog post by @marcbonten.bsky.social: letstalkscience.eu/2025/11/04/l...
Join the discussion 👇🏽
November 7, 2025 at 8:57 AM
💉Early BCG vaccination could save newborn lives. A new RCT from India shows a nearly 20% drop in neonatal mortality simply by administering vaccines earlier.
🔗 Read the latest blog post by @marcbonten.bsky.social: letstalkscience.eu/2025/11/04/l...
Join the discussion 👇🏽
🔗 Read the latest blog post by @marcbonten.bsky.social: letstalkscience.eu/2025/11/04/l...
Join the discussion 👇🏽
💡 The Penta BFA provides recognition & funding to individuals driving change in maternal & child health. Honour a leader who is advancing equitable health outcomes & combatting infectious disease.
Deadline for nominations has been extended to 15 November!
👉🏼 Submit your nomination: penta-id.org/bfa/
Deadline for nominations has been extended to 15 November!
👉🏼 Submit your nomination: penta-id.org/bfa/
Incredible nominations are already coming in for #BFA2025 & we can’t wait to celebrate more champions.
Our past Penta BFA winners prove that local heroes can change global health.
Entries close 15 November.
Nominate your hero today! www.penta-id.org/bfa
Our past Penta BFA winners prove that local heroes can change global health.
Entries close 15 November.
Nominate your hero today! www.penta-id.org/bfa
November 6, 2025 at 10:48 AM
💡 The Penta BFA provides recognition & funding to individuals driving change in maternal & child health. Honour a leader who is advancing equitable health outcomes & combatting infectious disease.
Deadline for nominations has been extended to 15 November!
👉🏼 Submit your nomination: penta-id.org/bfa/
Deadline for nominations has been extended to 15 November!
👉🏼 Submit your nomination: penta-id.org/bfa/
🚨 1 in 6 bacterial infections is now antibiotic-resistant. The new WHO GLASS Report demands immediate action.
Ecraid is Europe's answer. We're bridging the crisis-to-solution gap.
👉🏽Read how: bit.ly/WHOGLASS
Ecraid is Europe's answer. We're bridging the crisis-to-solution gap.
👉🏽Read how: bit.ly/WHOGLASS
November 3, 2025 at 1:32 PM
🚨 1 in 6 bacterial infections is now antibiotic-resistant. The new WHO GLASS Report demands immediate action.
Ecraid is Europe's answer. We're bridging the crisis-to-solution gap.
👉🏽Read how: bit.ly/WHOGLASS
Ecraid is Europe's answer. We're bridging the crisis-to-solution gap.
👉🏽Read how: bit.ly/WHOGLASS
🦠 New tool to track #antibioticresistance: the Emerging Resistance Index (ERI).
💡Using data from 38 surveillance systems across Europe, researchers found rapid resistance emerging to all new Gram-negative antibiotics.
The ERI could help guide surveillance & policy!
👉Read the article bit.ly/4hgk51g
💡Using data from 38 surveillance systems across Europe, researchers found rapid resistance emerging to all new Gram-negative antibiotics.
The ERI could help guide surveillance & policy!
👉Read the article bit.ly/4hgk51g
October 20, 2025 at 7:24 AM
🦠 New tool to track #antibioticresistance: the Emerging Resistance Index (ERI).
💡Using data from 38 surveillance systems across Europe, researchers found rapid resistance emerging to all new Gram-negative antibiotics.
The ERI could help guide surveillance & policy!
👉Read the article bit.ly/4hgk51g
💡Using data from 38 surveillance systems across Europe, researchers found rapid resistance emerging to all new Gram-negative antibiotics.
The ERI could help guide surveillance & policy!
👉Read the article bit.ly/4hgk51g
Meet Eveline Verheijen, our new Site Management Organisation (SMO) Manager!
🔬 Eveline leads our vaccination site in Utrecht - one of the top-performing study sites in NL. Her focus on collaboration, quality & efficiency helps accelerate clinical research.
🔎Read the full interview: bit.ly/SMO-Eveline
🔬 Eveline leads our vaccination site in Utrecht - one of the top-performing study sites in NL. Her focus on collaboration, quality & efficiency helps accelerate clinical research.
🔎Read the full interview: bit.ly/SMO-Eveline
October 17, 2025 at 12:14 PM
Meet Eveline Verheijen, our new Site Management Organisation (SMO) Manager!
🔬 Eveline leads our vaccination site in Utrecht - one of the top-performing study sites in NL. Her focus on collaboration, quality & efficiency helps accelerate clinical research.
🔎Read the full interview: bit.ly/SMO-Eveline
🔬 Eveline leads our vaccination site in Utrecht - one of the top-performing study sites in NL. Her focus on collaboration, quality & efficiency helps accelerate clinical research.
🔎Read the full interview: bit.ly/SMO-Eveline
💡 The Penta Brighter Future Award provides essential recognition and funding to individuals driving change in maternal and child health.
Honour a leader who is advancing equitable health outcomes and combatting infectious disease at the community level.
👉🏼 Submit your nomination: penta-id.org/bfa/
Honour a leader who is advancing equitable health outcomes and combatting infectious disease at the community level.
👉🏼 Submit your nomination: penta-id.org/bfa/
October 16, 2025 at 9:02 AM
💡 The Penta Brighter Future Award provides essential recognition and funding to individuals driving change in maternal and child health.
Honour a leader who is advancing equitable health outcomes and combatting infectious disease at the community level.
👉🏼 Submit your nomination: penta-id.org/bfa/
Honour a leader who is advancing equitable health outcomes and combatting infectious disease at the community level.
👉🏼 Submit your nomination: penta-id.org/bfa/
📩 Our latest newsletter is out!
Discover significant developments at Ecraid, including the launch of our new campaign to foster strategic collaborations, #PartnerForImpact!
📫 Stay informed, subscribe now bit.ly/43kBWhJ
#PartnerWithEcraid #ClinicalResearch #InfectiousDiseases #Education #Knowledge
Discover significant developments at Ecraid, including the launch of our new campaign to foster strategic collaborations, #PartnerForImpact!
📫 Stay informed, subscribe now bit.ly/43kBWhJ
#PartnerWithEcraid #ClinicalResearch #InfectiousDiseases #Education #Knowledge
October 14, 2025 at 10:54 AM
📩 Our latest newsletter is out!
Discover significant developments at Ecraid, including the launch of our new campaign to foster strategic collaborations, #PartnerForImpact!
📫 Stay informed, subscribe now bit.ly/43kBWhJ
#PartnerWithEcraid #ClinicalResearch #InfectiousDiseases #Education #Knowledge
Discover significant developments at Ecraid, including the launch of our new campaign to foster strategic collaborations, #PartnerForImpact!
📫 Stay informed, subscribe now bit.ly/43kBWhJ
#PartnerWithEcraid #ClinicalResearch #InfectiousDiseases #Education #Knowledge
@marcbonten.bsky.social has dedicated his career to advancing #clinicalmicrobiology & combatting #antimicrobialresistance. In his new role as Vice-Dean Education at @umcutrecht.bsky.social
he continues to inspire the next generation of healthcare scientists & researchers: ecraid.eu/articles/edu...
he continues to inspire the next generation of healthcare scientists & researchers: ecraid.eu/articles/edu...
October 13, 2025 at 12:08 PM
@marcbonten.bsky.social has dedicated his career to advancing #clinicalmicrobiology & combatting #antimicrobialresistance. In his new role as Vice-Dean Education at @umcutrecht.bsky.social
he continues to inspire the next generation of healthcare scientists & researchers: ecraid.eu/articles/edu...
he continues to inspire the next generation of healthcare scientists & researchers: ecraid.eu/articles/edu...
The #ECDC report on C. auris shows gaps in EU surveillance & IPC. Ecraid is built to fill them:
- Warm-base network for faster diagnosis, prevention, & treatment.
- Single-access infrastructure breaks research silos.
We strengthen the defense against future #AMR threats: bit.ly/PartnerForIm...
- Warm-base network for faster diagnosis, prevention, & treatment.
- Single-access infrastructure breaks research silos.
We strengthen the defense against future #AMR threats: bit.ly/PartnerForIm...
Accelerate Infectious Disease Trials | Ecraid
Accelerate infectious disease research with Ecraid's innovative trial designs and extensive European network for efficient, high-quality clinical trials.
bit.ly
October 7, 2025 at 11:56 AM
The #ECDC report on C. auris shows gaps in EU surveillance & IPC. Ecraid is built to fill them:
- Warm-base network for faster diagnosis, prevention, & treatment.
- Single-access infrastructure breaks research silos.
We strengthen the defense against future #AMR threats: bit.ly/PartnerForIm...
- Warm-base network for faster diagnosis, prevention, & treatment.
- Single-access infrastructure breaks research silos.
We strengthen the defense against future #AMR threats: bit.ly/PartnerForIm...
Which antibiotic works best for treating moderate to severe community-acquired pneumonia (CAP) 🫁 ? A commentary in Clinical Microbiology and Infection emphasises the urgent need for stronger evidence - because patients deserve better 👇🏼
@escmid.bsky.social @cmicomms.bsky.social
@escmid.bsky.social @cmicomms.bsky.social
Now online: our commentary on the topic of initial antibiotic therapy in patients hospitalized with pneumonia. 👇
💣 Spoiler alert: we need to change rules if we want the best therapy for our patients.
www.clinicalmicrobiologyandinfection.org/action/showP...
💣 Spoiler alert: we need to change rules if we want the best therapy for our patients.
www.clinicalmicrobiologyandinfection.org/action/showP...
Empiric antibiotics for moderate-severe community-Acquired Pneumonia: We ought to serve patients better!
Each day thousands of patients are hospitalized worldwide with Community-Acquired
Pneumonia (CAP), either radiologically confirmed or presumed based on clinical symptoms
only, and each day physicians ...
www.clinicalmicrobiologyandinfection.org
September 30, 2025 at 1:15 PM
Which antibiotic works best for treating moderate to severe community-acquired pneumonia (CAP) 🫁 ? A commentary in Clinical Microbiology and Infection emphasises the urgent need for stronger evidence - because patients deserve better 👇🏼
@escmid.bsky.social @cmicomms.bsky.social
@escmid.bsky.social @cmicomms.bsky.social
On 15-SEP, the annual #PNEUMO EU F2F meeting with Ecraid’s operational team and funder MSD took place.
It was a fruitful meeting held at MSD headquarters in Haarlem, with a very nice tour around their facility.
Thanks to Kelly Johnson & #MSD NL for the hospitality & for continuous collaboration!
It was a fruitful meeting held at MSD headquarters in Haarlem, with a very nice tour around their facility.
Thanks to Kelly Johnson & #MSD NL for the hospitality & for continuous collaboration!
September 24, 2025 at 7:43 AM